3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a juicy target for small biotech companies looking to develop the next big drug. It also makes those biotechs potentially lucrative investments, for those who are daring.

But which businesses have the best chance at success in a field where many, including big pharmas, have tried and failed? Let's take a look at three of the myriad of competitors to figure it out.

There is a trio of popular pre-revenue biotechs angling for the NASH market that you may have heard of: Madrigal Pharmaceuticals (NASDAQ: MDGL), Terns Pharmaceuticals (NASDAQ: TERN), and Viking Therapeutics (NASDAQ: VKTX). Terns has a program that's anticipated to enter phase 2b/3 in 2024. Viking's phase 2b trial is already in progress.

Continue reading

Source Fool.com